The content on this site is intended for healthcare professionals only
Dr Valentin Goede presented promising outcomes for elderly CLL patients at the 18th Congress of the European Hematology Association in Stockholm.
CLL is the most common leukaemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
It has been an unresolved question whether (i) combination treatment with the chemotherapeutic drug chlorambucil plus a monoclonal CD20 antibody improves outcomes for such patients compared to treatment with chlorambucil alone and (ii) these patients benefit from the use of the novel CD20 antibody obinutuzumab (GA101) relative to the approved CD20 antibody rituximab.
ecancer's filming at EHA has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Choosing the right Tyrosine Kinase Inhibitors (TKI) for CML Patients
Advancements in paediatric Acute lymphoblastic leukemia management
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Choosing 1st line TKI Wisely in patients with CML
